Protocol Section List

Home Icon Home Search Icon Search Alerts Icon Stocks Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs eRecord Icon eRecord
Main Search All Studies All Organizations Report Bug
Protocol Section List
You are on Page 2537 of 2568:
2527 2528 2529 2530 2531 2532 2533 2534 2535 2536 2537 2538 2539 2540 2541 2542 2543 2544 2545 2546 2547

Protocol Sections: The Identification Through IPD Sharing Statement are Modules For This Protocol Section

NCTID Brief Title Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Oversight Description Conditions View
NCT00017823 Acupressure to Treat Nausea and Vomiting in HIVAIDS Patients Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00017810 The Healthy Life Choices Project in HIV-Positive Patients Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00017797 Problems Associated With the Use of Anti-HIV Drugs in HIV-Infected Pregnant Women Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00017784 Valganciclovir in Patients With CMV Retinitis and AIDS Who Cannot Take Drugs by Injection Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00017771 Nerve Damage in Patients With HIV Infection Who Have Been Treated With Anti-HIV Drugs Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00017758 The Effect of Efavirenz and Nelfinavir on the Blood Levels of Certain Lipid-Lowering Drugs Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00017745 PhenotypeGenotype Correlations in Neuromuscular Disorders Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00017732 Estimation of the Carrier Frequency and Incidence of Smith-Lemli-Opitz Syndrome in African Americans Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00017719 Combination Treatment With and Without Protease Inhibitors for Women Who Begin Therapy for HIV Infection During Pregnancy Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00017706 Effectiveness of Primary Care Physicians in Delivering Weight Control Counseling Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00017693 Recombinant Human IL-4 Receptor Used in Treatment of Asthma Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00017680 Study of High-Dose Melphalan and Autologous Stem Cell Transplantation in Patients With Primary Light Chain Amyloidosis Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00017654 Study of Allogeneic Bone Marrow and T-Cell Depleted CD34 Peripheral Blood Stem Cell Transplantation in Patients With Aplastic Anemia Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00017641 Phase I Study of Immune Ablation and CD34 Peripheral Blood Stem Cell Support in Patients With Systemic Lupus Erythematosus Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00017628 Phase I Study of High-Dose Cyclophosphamide and Total Body Irradiation With T Lymphocyte-Depleted Autologous Peripheral Blood Stem Cell or Bone Marrow Rescue in Patients With Multiple Sclerosis Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00017602 Dexamethasone With or Without Oblimersen in Treating Patients With Relapsed or Refractory Multiple Myeloma Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00017589 Oblimersen and Gemtuzumab Ozogamicin in Treating Older Patients With Relapsed Acute Myeloid Leukemia Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00017576 Calcitriol and Carboplatin in Treating Patients With Stage IV Prostate Cancer That Has Not Responded to Hormone Therapy Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00017563 Combination Chemotherapy Followed by Surgery in Treating Patients With Localized Prostate Cancer Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00017550 Antithymocyte Globulin Compared With Supportive Care in Treating Patients With Myelodysplastic Syndrome Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00017537 Vaccine Therapy in Treating Patients With Metastatic or Recurrent Cancer Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00017524 AG2037 in Treating Patients With Advanced Metastatic or Recurrent Solid Tumors Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00017511 Cevimeline in Treating Patients With Dry Mouth Caused by Radiation Therapy for Head and Neck Cancer Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00017498 Gemcitabine in Treating Patients With Recurrent or Metastatic Adenoid Cystic Cancer of the Head and Neck Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00017485 Photodynamic Therapy in Treating Patients With Basal Cell Skin Cancer Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00017472 Monoclonal Antibody Therapy in Treating Patients With Chronic Lymphocytic Leukemia Lymphocytic Lymphoma Acute Lymphoblastic Leukemia or Acute Myeloid Leukemia Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00017459 Cisplatin Plus Vinorelbine With or Without Tirapazamine in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00017446 CP4071 in Treating Patients With Locally Advanced or Metastatic Soft Tissue Sarcoma Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00017433 Arsenic Trioxide in Treating Patients With Multiple Myeloma Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00017407 Carboplatin and Paclitaxel With or Without ISIS 3521 in Treating Patients With Non-Small Cell Lung Cancer Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00017394 Bevacizumab Plus Vinorelbine in Treating Patients With Stage IV Breast Cancer Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00017381 Monoclonal Antibody Therapy and Peripheral Stem Cell Transplant in Treating Patients With Non-Hodgkins Lymphoma Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00017368 Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Children With Newly Diagnosed Neuroblastoma Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00017355 Vaccine Therapy in Treating Patients With Metastatic Melanoma Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00017342 Bryostatin 1 and Cytarabine in Treating Patients With Relapsed Acute Myelogenous Leukemia Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00017329 PS-341 in Treating Patients With Metastatic Kidney Cancer Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00017316 Thalidomide and SU5416 in Treating Patients With Metastatic Melanoma Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00017303 Combination Chemotherapy Plus IM-862 in Treating Patients With Resected Stage III Ovarian Cancer or Primary Peritoneal Cancer Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00017290 Combination Chemotherapy Followed By Vaccine Therapy Plus Sargramostim in Treating Patients With Stage III or Stage IV Non-Hodgkins Lymphoma Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00017277 Radiation Therapy With or Without Epoetin Alfa in Treating Patients With Head and Neck Cancer Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00017264 Atrasentan in Treating Patients With Progressive or Recurrent Malignant Glioma Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00017251 Combination Chemotherapy Plus Oblimersen in Treating Patients With Previously Untreated Extensive-Stage Small Cell Lung Cancer Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00017238 KRN5500 in Treating Patients With Solid Tumors Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00017225 Chemotherapy and Radiation Therapy With or Without Peripheral Stem Cell Transplantation in Treating Patients With Neuroblastoma Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00017212 DX-8951f in Treating Patients With Metastatic Stomach Cancer Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00017199 PS-341 in Treating Patients With Metastatic Neuroendocrine Tumors Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00017186 Gemcitabine and Epirubicin in Treating Patients With Malignant Mesothelioma Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00017173 S0011 Gene Therapy Surgery Followed by Chemo RT in Newly Diagnosed Cancer of the Mouth or Throat Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00017160 Combination Chemotherapy Radiation Therapy and Surgery in Treating Patients With Primary or Recurrent Sarcoma Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00017147 S0001 RT and Carmustine With or Without O6BG in Patients With New Glioblastoma Multiforme or Gliosarcoma Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00017134 Fenretinide Followed by Surgery Compared With Surgery Alone in Preventing Ovarian Cancer in Patients at Increased Risk Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00017121 Inhaled Sargramostim in Treating Patients With Melanoma Metastatic to the Lung Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00017108 Chlorambucil in Treating Patients With Advanced Chronic Lymphocytic Leukemia Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00017095 Biomarker p53 Gene Analysis and Combination Chemotherapy Followed by Radiation Therapy and Surgery in Treating Women With Large Operable or Locally Advanced or Inflammatory Breast Cancer Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00017082 Oxaliplatin in Treating Patients With Recurrent Metastatic Colorectal Cancer Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00017069 Arsenic Trioxide and Dexamethasone in Treating Patients With Recurrent or Refractory Stage II or Stage III Multiple Myeloma Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00017056 BMS-247550 in Treating Patients With Recurrent Metastatic Stomach Cancer That Has Been Previously Treated With Chemotherapy Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00017043 BMS-247550 in Treating Patients With Metastatic Stomach Cancer Previously Treated With Chemotherapy Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00017030 Ecteinascidin 743 in Treating Patients With Unresectable Advanced or Metastatic Soft Tissue Sarcoma Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00017017 CT-2103 in Treating Patients With Recurrent Ovarian Epithelial or Fallopian Tube Cancer or Primary Peritoneal Cancer Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00017004 Radiation Therapy and Cisplatin With or Without Epoetin Alfa in Treating Patients With Cervical Cancer and Anemia Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00016991 ZD 1839 in Treating Patients With Glioblastoma Multiforme in First Relapse Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00016978 Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer Previously Treated With Irinotecan Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00016965 BMS-247550 in Treating Patients With Advanced Pancreatic Cancer Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00016952 Irinotecan or Fluorouracil Plus Leucovorin in Treating Patients With Previously Treated Metastatic Colorectal Cancer Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00016939 Flavopiridol in Treating Patients With Unresectable or Metastatic Kidney Cancer Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00016926 Capecitabine in Treating Patients With Advanced Persistent or Recurrent Cervical Cancer Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00016913 Chemotherapy Hormone Therapy and Radiation Therapy in Treating Patients With Locally Advanced Prostate Cancer Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00016900 PNU-93914 in Treating Patients With Locally Advanced or Metastatic Cancer of the Esophagus Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00016887 Chemotherapy Followed by Radiation Therapy and Peripheral Stem Cell Transplant Compared With Chemotherapy Plus Interferon Alfa in Treating Patients With Stage III or Stage IV Mantle Cell Lymphoma Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00016874 3-AP Plus Cisplatin and Paclitaxel in Treating Patients With Advanced or Metastatic Cancer Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00016861 Irinotecan in Treating Children With Refractory or Progressive Solid Tumors Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00016848 Effects of Dietary Carbohydrate and Fat on Hormones Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00016835 Treating Periodontal Infection Effects on Glycemic Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00016796 Language Stimuli Screening in Children Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00016783 Stopping and Restarting Anti-HIV Drugs in Children and Adolescents With Low Blood Levels of HIV Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00016744 PhenylbutyrateGenistein Duotherapy in Delta F508-Homozygousfor Cystic Fibrosis Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00016731 Adolescence Puberty and Emotion Regulation Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00016718 Safety and Effectiveness of Emtricitabine Efavirenz and Didanosine in HIV Infected Children Who Have Taken Few or No Anti-HIV Drugs Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00016692 Safety and Tolerability of Z-100 in Patients With Early HIV Infection Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00016679 1-Octanol to Treat Essential Tremor Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00016666 Clinical Trial of Propranolol for Seasonal Affective Disorder Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00016653 Creatine and Glutamine in Steroid-Naive Duchenne Muscular Dystrophy Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00016627 Linkage Study in Familial Pulmonary Fibrosis Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00016601 Depo-Medroxyprogesterone Acetate DMPA Depo-Provera Use With Certain Anti-HIV Drugs in HIV-Infected Women Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00016588 Tenofovir Disoproxil Fumarate TDF in HIV-1 Patients Who Have Never Taken Anti-HIV Drugs Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00016562 Cause and Pathogenesis of Neurometabolic Disorders Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00016549 Bevacizumab to Treat Inflammatory Breast Cancer or Locally Advanced Breast Cancer Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00016536 Effects of BufferGel and PRO 20005 Gel in Men Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00016523 Inhaled Nitric Oxide for Preterm Infants With Severe Respiratory Failure Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00016510 Differences in Brain Processing of First and Second Languages Korean and English Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00016497 Adenoidectomy for Otitis Media in 2-3 Year Old Children Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00016471 A Genetic Analysis of Usher Syndrome in Ashkenazi Jews Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00016458 Phase II Pilot Study of Cyclophosphamide and Rabbit Anti-Thymocyte Globulin as Salvage Therapy in Patients With Diffuse Systemic Sclerosis Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00016445 Phase II Study of Growth Hormone in Children With Cystic Fibrosis Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00016432 Exemestane in Treating Postmenopausal Women With Resected Stage I Stage II or Stage IIIA Breast Cancer Who Have Completed 5 Years of Tamoxifen Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00016419 S0020 Immunosuppressive Therapy in Treating Patients With Myelodysplastic Syndrome Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00016406 S0012 Doxorubicin Cyclophosphamide and Paclitaxel With or Without Filgrastim in Treating Women With Inflammatory or Locally Advanced Breast Cancer Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00016393 BMS-247550 in Treating Patients With Prostate Cancer That Has Not Responded to Hormone Therapy Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00016380 Ondansetron WithOut Dexamethasone to Prevent Vomiting in Patients Receiving Radiation to the Upper Abdomen Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00016367 Cisplatin and Gemcitabine Plus Trastuzumab in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00016354 Benzoylphenylurea in Treating Patients With Advanced Solid Tumors Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00016341 Combination Chemotherapy Compared With Hormone Therapy in Treating Patients With Recurrent Stage III or Stage IV Endometrial Cancer Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00016328 CCI-779 in Treating Patients With Recurrent Glioblastoma Multiforme Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00016315 Gemcitabine Carboplatin or Paclitaxel Plus Radiation Therapy in Treating Patients With Stage IIIA or IIIB Non-Small Cell Lung Cancer Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00016302 Combination Chemotherapy in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00016289 Interleukin-12 in Treating Patients With Ovarian Epithelial Cancer or Primary Peritoneal Cancer Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00016276 Combination Chemotherapy Surgery and Radiation Therapy With or Without Dexrazoxane and Trastuzumab in Treating Women With Stage III or Stage IV Breast Cancer Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00016263 Dacarbazine With or Without Oblimersen G3139 in Treating Patients With Advanced Malignant Melanoma Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00016250 Ro 31-7453 in Treating Patients With Recurrent or Refractory Metastatic Colorectal Cancer Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00016237 Interleukin-2 Combined With Monoclonal Antibody Therapy in Treating Patients With Kidney Bladder or Lung Cancer That Has Not Responded to Previous Treatment Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00016224 Thalidomide in Treating Patients With Refractory or Resistant Epithelial Ovarian Cancer Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00016211 Radiation Therapy to Prevent Brain Metastases in Patients With Previously Treated Extensive-Stage Small Cell Lung Cancer Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00016198 Fluorouracil and Leucovorin With or Without Oxaliplatin in Treating Patients With Recurrent Metastatic Colorectal Cancer Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00016185 Flavopiridol and Docetaxel in Treating Patients With Advanced Solid Tumors Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00016172 ZD0473 and Doxorubicin in Treating Patients With Advanced Solid Tumors or Lymphoma Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00016159 Chemotherapy Plus Monoclonal Antibody in Treating Patients With Acute Promyelocytic Leukemia Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00016146 Vaccine Therapy Plus Biological Therapy in Treating Patients With Prostate Cancer Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00016133 Vaccine Therapy in Treating Patients With Stage II or Stage III Colon Cancer That Has Been Removed During Surgery Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00016107 Combination Chemotherapy Plus Bevacizumab in Treating Patients With Metastatic Prostate Cancer Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00016094 S0108 Bevacizumab in Treating Patients With Non-Hodgkins Lymphoma Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00016081 Ribavirin Compared With Standard Care in Treating Patients With Respiratory Syncytial Virus Following Stem Cell Transplantation Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00016068 Valganciclovir to Prevent Cytomegalovirus Infection in Patients Following Donor Stem Cell Transplantation Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00016055 Biological Therapy and Temozolomide in Treating Patients With Metastatic Melanoma Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00016042 Fluorouracil and Biological Therapy in Treating Patients With Metastatic Kidney or Colorectal Cancer Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00016029 Comparison of Barium Enema Computed Tomographic Colonography and Colonoscopy in Detecting Colon Cancer Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00016016 Flavopiridol Cytarabine and Mitoxantrone in Treating Patients With Acute Leukemia Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00015990 Thalidomide in Treating Patients With Myelodysplastic Syndrome Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00015977 Vaccine Therapy Plus Interleukin-12 in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00015964 ZD 1839 in Treating Patients With Metastatic or Recurrent Cancer of the Head and Neck Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00015951 Bevacizumab Cytarabine and Mitoxantrone on Treating Patients With Hematologic Cancers Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00015938 S0102 Docetaxel Vinorelbine and Filgrastim in Treating Women With Stage IV Breast Cancer Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00015925 MS-275 in Treating Patients With Hematologic Cancer Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00015912 Interferon Alfa Plus Thalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkins Lymphoma Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00015899 SCH 66336 in Treating Children With Recurrent or Progressive Brain Tumors Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00015886 Combination Chemotherapy in Treating Women With Breast Cancer That is Metastatic or Cannot be Treated With Surgery Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00015873 Comparison of Different Combination Chemotherapy Regimens in Treating Infants With Acute Lymphoblastic Leukemia Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00015860 STI571 Plus Combination Chemotherapy in Treating Patients With Chronic Myelogenous Leukemia or Acute Lymphocytic Leukemia Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00015847 Imatinib Mesylate and Interferon Alfa in Treating Patients With Chronic Myelogenous Leukemia Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00015834 STI571 Plus Cytarabine in Treating Patients With Chronic Myelogenous Leukemia Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00015821 Thalidomide in Treating Patients With Myelofibrosis Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00015808 Safety Study of Idebenone to Treat Friedreichs Ataxia Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00015795 Study of Air Stream in Voice Production Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00015782 The Natural History and Pathogenesis of Mucolipidosis Type IV Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00015769 Pilot Study of Levetiracetam Keppra Registered Trademark for Bipolar Illness Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00015756 Tissue Collection From People With Cystic Fibrosis Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00015717 Magnetic Resonance Imaging to Investigate Silent Strokes During Neck and Skull Angioplasty Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00015704 Effect of Interleukin-2 on HIV Treatment Interruption Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00015691 Metformin and Rosiglitazone Alone or in Combination in HIV-Infected Patients With Insulin and Fat Abnormalities Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00015678 Effects of Flumazenil on Brain Excitability Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00015665 Emergency Use of Voriconazole in Patients With Life-Threatening Invasive Fungal Infections Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00015652 Interleukin-2 IL-2 Pegylated Interferon PEG-IFN Alfa-2b and Ribavirin RBV Treatment in Patients With Hepatitis C and HIV Coinfection Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00015639 Identification of Donors of CD36-Deficient Platelets Among Japanese Individuals on the NIH Campus Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00015626 A Clinical Trial to Prevent the Complications of Insulin Resistance Including Type-2 Diabetes Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00015613 Farm Work Preterm Low Birthweight Among Hispanic Women Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00015600 Community-Based Environmental Health Intervention Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00015587 Molecular Epidemiology of Childhood Leukemia Aka The California Childhood Leukemia Study Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00015574 Air Pollution and Implantable Cardioverter Defibrillators Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00015561 Pesticides--Health Fertility and Reproductive Risk Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00015548 CATIE-Alzheimers Disease Trial Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00015483 Hematotoxic Effects of Particulate Exposure Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00015470 Diagnostic Evaluation of Patients With Neuromuscular Disease Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00015457 Amlodipine Plus Botulinum Toxin for Focal Dystonia Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00015444 Screening and Natural History Primary Lateral Sclerosis and Related Disorders Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00015431 Immune System and Gut Abnormalities in Patients With Common Variable Immunodeficiency With and Without Gastrointestinal Symptoms Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00015340 BuprenorphineNaloxone in the Treatment of Heroin Dependence - 14 Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00015301 Methylphenidate Raclopride Positron Emission Tomography PET Test - 11 Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00015288 Buprenorphine and Naloxone Combination Study - 10 Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00015275 Pathophysiological Subtyping of Abnormalities in Cocaine Dependence - 9 Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00015249 Prepulse Inhibition of Startle in Cocaine Dependence - 7 Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00015236 Modeling Impaired Judgement in Cocaine Abusers - 6 Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00015223 Methylphenidate in the Treatment of Cocaine Dependent Patients With Adult Attention Deficit Hyperactivity Disorder - 5 Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00015210 Nefazodone in the Treatment of Cocaine Dependence and Depression - 4 Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00015171 Buprenorphine and Naloxone for the Treatment of Opiate Dependence - 1 Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00015132 Tiagabine Sertraline or Donepezil for the Treatment of Cocaine Dependence - 9 Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00015106 Resperine Gabapentin or Lamotrigine for the Treatment of Cocaine Dependence 2 - 7 Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00015080 Naltrexone in Treatment of Cocaine Dependence - 5 Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00015067 Cocaine-Methylphendidate Interaction Study - 4 Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00015054 Methylphendidate Treatment of Cocaine Dependent Patients With Attention Deficit Hyperactivity Disorder - 3 Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00015041 Buprenorphine Dose Escalation Trial for Treatment of Non-Dependent Opiate Users - 2 Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00015028 BuprenorphineNaloxone for Opiate-Dependence Treatment - 1 Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00015015 Dichloroacetate Kinetics Metabolism and Toxicology Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00015002 Repeat Antenatal Steroids Trial Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00014989 Beneficial Effects of Antenatal Magnesium Sulfate BEAM Trial Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00014976 Physiologic Studies of Spasticity Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00014963 Biomarkers of Benzene Exposure in Inner City Residents Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00014950 Benefits and Risks of Newborn Screening for Cystic Fibrosis Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00014937 Simplified Drug Regimens for HIV Patients in ACTG 388 or Patients Who Responded to A First Potent Combination Regimen Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00014911 Islet Transplantation for Type 1 Diabetes Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00014898 Attention Deficit Disorder and Exposure to Lead Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00014885 Bone Lead Levels and College Achievement Scores Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00014872 Genetic Epidemiology and Energy Metabolism in Black Girls Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00014859 Epidemiology of Surfactant Protein-B Deficiency Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00014833 Life Course Socioeconomic Status Social Context and Cardiovascular Disease Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00014820 Occupation and Asthma in an Urban Low Income Population Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00014807 Reducing Pesticide Exposure in Minority Families Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00014794 Positron Emission Tomography and Magnetic Resonance Imaging to Evaluate Synovial Blood Flow in Rheumatoid Arthritis Patients Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00014781 Study of Hepatic Glucose Production and De Novo Lipogenesis in Patients With Cystic Fibrosis Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00014768 Study of Metabolic Effects of Pregnancy in Women With Cystic Fibrosis Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00014755 Phase I Pilot Study of Total-Body Irradiation Anti-Thymocyte Globulin and Cyclophosphamide Followed By Syngeneic or Autologous Peripheral Blood Stem Cell Transplantation in Patients With Multiple Sclerosis Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View